Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 1/2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Neoplasm Metastasis 14Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 8Ovarian Neoplasms 6Colorectal Neoplasms 6Uveal Melanoma 5Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Mesothelioma 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma, Transitional Cell 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Lung Neoplasms 4Carcinoma, Merkel Cell 4Advanced Cancer 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Liver Neoplasms 3Hodgkin Disease 3Head and Neck Neoplasms 3Carcinoma 3

Interventions

Dexamethasone 133Lenalidomide 58Bortezomib 56Calcium Dobesilate 43Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9Mycophenolic Acid 9pembrolizumab 8isatuximab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Ipilimumab × Clear all
NCT02681302 2026-04-03

CPIT001

Hackensack Meridian Health

Phase 1/2 Terminated
46 enrolled 13 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04635735 2023-03-23

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
3 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡